SCHEMBL7418205

SCHEMBL7418205

CC(C)C[C@H](NC(=O)COc1ccccc1-c1ccccc1)C(=O)C(C(=O)CF)C(N)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.53
HTT P42858 3/20 0.53
MAPT P10636 3/20 0.53
MAPK1 P28482 3/20 0.53
USP2 O75604 1/20 0.53
CASP1 P29466 3/20 0.51
CASP3 P42574 3/20 0.51
CASP7 P55210 3/20 0.51
CASP6 P55212 3/20 0.51
CASP8 Q14790 3/20 0.51
ALDH1A1 P00352 7/20 0.46
KDM4E B2RXH2 5/20 0.46
NPSR1 Q6W5P4 2/20 0.41
L3MBTL1 Q9Y468 4/20 0.40
PLA2G1B P04054 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6832902 0.83 MME (0.39) LMNARAB9AKMT2A
SCHEMBL5495598 0.80 CASP3 (0.56) LMNAHTTMAPTMAPK1USP2
SCHEMBL5495594 0.80 CASP3 (0.56) LMNAHTTMAPTMAPK1USP2
SCHEMBL7404706 0.76 CASP3 (0.57) LMNAMAPTCASP1CASP3CASP7
SCHEMBL7418208 0.76 LMNA (0.52) LMNAHTTMAPTMAPK1USP2
SCHEMBL6830895 0.74 CASP3 (0.43) CASP1CASP3CASP7CASP6CASP8
SCHEMBL14598409 0.71 CASP3 (0.58) LMNAHTTMAPTMAPK1USP2
SCHEMBL7467278 0.70 CASP3 (0.53) LMNAMAPTCASP1CASP3CASP7
SCHEMBL7253535 0.70 ALDH1A1 (0.60) LMNAHTTMAPTMAPK1USP2
SCHEMBL7417959 0.69 BCL2L1 (0.41) CASP3CASP6CASP8ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091089-A1 (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases KARANEWSKY DONALD S (US) 2002-07-11 US disclosed
EP-1123272-A1 (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES Idun Pharmaceuticals, Inc. (US) 2001-08-16 EP disclosed
WO-2000023421-A1 (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES IDUN PHARMACEUTICALS, INC. (US) 2000-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091089-A1 (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases DPP3, IAPP, CASP3 LMNA 3785/4885HTT 1006/4885MAPT 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.